Brighter Year End Report 2016.

The full Year End Report 2016 is available on Brighter's website www.brighter.se. A pdf copy is also attached to this press release.

Summary of the financial year January 1 to  December 31 2016.

• Operating income amounted to SEK 23,076 thousand (SEK 15,722 thousand).

• Profit after financial items amounted to SEK -14,731 thousand (-11,468 thousand).

• Earnings per share before dilution SEK -0.32 (SEK -0.24).

• Earnings per share after dilution SEK -0.32 (SEK -0.24).

Significant events during the period.

• 2016-11-30 – Brighter signs agreement to launch the diabetes solution Actiste in Indonesia.

• 2016-11-16 – Camanio Care AB secures funds amounting to SEK 9.4 million ahead of listing.

• 2016-10-25 – Brighter merges its jDome-business with Bestic and plans listing as an independent company.

• 2016-10-12 – The Swedish Patent and Registration Office grants Brighter’s patent application.

• 2016-10-12 – Brighter wins arbitration case against former development partner.

• 2016-10-11 – Brighter raises SEK 11.2 million through Private Placement.

• 2016-10-04 – Brighter receives breakthrough order regarding jDome BikeAround in Denmark.

Significant events after the period.

• 2017-02-20 – Brighter signs agreement with Sonat for global logistics solution.

• 2017-01-05 – Record date for distribution of shares in Camanio Care to Brighters shareholders has been set.

A message from the CEO.

In the fourth and final quarter of last year, we made several positive announcements that will transform our company. We strengthened our patent portfolio and signed an important agreement with the mobile network operator Indosat Ooredoo. We also formed a new and exciting company called Camanio Care, which is a merger between jDome and a company we acquired called Bestic AB. This new company will soon be listed on AktieTorget.

On the whole, we are extremely happy with our progress in 2016, but we now have our sights set on the future and we have extremely high expectations for 2017 and the years to come. It is great to see so many people interested in what we are doing! This is something we noticed at the events we took part in last autumn, including Stockholm Tech Fest and Health 2.0, where we received a lot of attention. There is a great deal of interest in finding new, innovative ways of streamlining healthcare and helping patients lead a better life; Actiste is viewed as a good example of this.

We believe that Brighter is in a good position to grow quickly as soon as Actiste is CE marked and launched on the market. Our success can be attributed to the partnerships that we have continued to secure over time, including those with Ericsson, Telia, Indosat Ooredoo and Sanmina. We recently signed an agreement with Sonat, which will help us to establish a scalable and effective logistics platform.

The company is currently in the middle of the industrialization phase, which has entailed heavy focus on preparations for the launch. For example, we have done injection molding tools for the production of Actiste, and we are continuously working with our partners on various aspects of the launch, both in Sweden and in Southeast Asia.

We are planning the initial launch in Sweden during the second half of 2017. We will then continue to scale up as we launch the solution in other countries and complete local registration processes. On the whole we are extremely satisfied with how things have gone so far in every area, and we cannot see anything that will disrupt our schedule, which will remain in place unless otherwise communicated.

As mentioned previously, we acquired a company called Bestic AB in October, which develops and markets a number of innovative products and services in welfare technology, with focus on quality of life. We subsequently merged it with jDome. There are obvious synergies. The products and services they both bring to Camanio Care are aimed at the same target group, and by increasing our resources we can reach customers more effectively both here at home and abroad. Camanio Care will also invest heavily in developing new products. At the beginning of the year we distributed some of our holdings to our existing shareholders; we will remain a major owner, even though we will not be the majority owner. We believe that Camanio Care is in a perfect position to become a leading company in welfare technology, which will benefit both us and our shareholders.

I would like to end by saying how wonderful it feels to see all the progress we are making with Actiste. The further we move into the industrialization phase, the closer we get to the launch – which can make the lives of millions of diabetics easier and streamline the entire care chain. Better and more modern care is clearly needed. This is something that we have become acutely aware of at the external events in which we have taken part. 

It is great to start the new year with so much to look forward to – not only for us as a company but also for society.

Truls Sjöstedt,
Founder and CEO of Brighter AB

For more information, please contact:
Truls Sjöstedt, CEO      
Tel: +46 709 73 46 00      
Email: truls.sjostedt@brighter.se 

Henrik Norström, COO      
Tel: +46 733 40 30 45      
Email: henrik.norstrom@brighter.se

About Brighter AB. 
Brighter develops solutions for data-driven and mobile health services. Through its intellectual property and its first launch Actiste®, the company creates a more efficient care chain with focus on the individual. The goal is to simplify, streamline and enhance the information flow of relevant and reliable data between the patient and health care professionals. Brighter is initially focused on diabetes care and care for the elderly, but there are opportunities in the future to operate on a broader level, spanning more diseases and treatment approaches. This is done through The Benefit Loop®, Brighter’s cloud-based service that continuously collects, analyzes and shares data on the user's terms.

The Company's shares are listed on NASDAQOMX FIRST NORTH/BRIG. Brighter's Certified Adviser is Remium Nordic AB, +46 (0)8 454 32 50, CorporateFinance@remium.com, www.remium.com.

This information is information that Brighter AB is obliged to make public pursuant to the EU Market Abuse Regulation and the Securities Markets Act. The information was submitted for publication, through the agency of the contact persons set out above, at 08:30 CET on 24 February 2017.